Generic Symproic Availability
Last updated on Jan 8, 2025.
Symproic is a brand name of naldemedine, approved by the FDA in the following formulation(s):
SYMPROIC (naldemedine tosylate - tablet;oral)
-
Manufacturer: BDSI
Approval date: March 23, 2017
Strength(s): EQ 0.2MG BASE [RLD]
Has a generic version of Symproic been approved?
No. There is currently no therapeutically equivalent version of Symproic available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Symproic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
Patent 10,952,968
Issued: March 23, 2021
Inventor(s): Mashimo Akira & Ichio Shunji & Tamura Yoshinori & Noguchi Kouichi
Assignee(s): SHIONOGI & CO., LTD.The solid preparation which improved the dissolution profile and the stability of the 6,7-unsaturation-7-carbamoyl morphinan derivative is provided. When 6,7-unsaturation-7-carbamoyl morphinan derivative, croscarmellose sodium and ferric oxide were contained, not titanium oxide in the solid preparations and the coating solid preparations, a dissolution rate after 15 minutes of the dissolution test is more than 85%, and stability, particularly, light stability can be improve.
Patent expiration dates:
- May 13, 2033✓✓
- May 13, 2033
-
Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same
Patent 9,108,975
Issued: August 18, 2015
Inventor(s): Tamura Yoshinori & Noguchi Kouichi & Inagaki Masanao & Morimoto Kenji & Haga Nobuhiro & Oda Shinichi & Omura Sohei
Assignee(s): Shionogi & Co., LTD.Stable crystalline forms of a compound represented by the formula (IA):
Patent expiration dates:
- November 11, 2031✓✓
- November 11, 2031
-
6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Patent RE46365
Issued: April 11, 2017
Inventor(s): Inagaki Masanao & Hara Shin-ichiro & Haga Nobuhiro & Tamura Yoshinori & Goto Yoshihisa & Hasegawa Tsuyoshi
Assignee(s): Shionogi & Co., Ltd.A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation. A compound represented by the formula (I):
Patent expiration dates:
- January 11, 2028✓✓
- January 11, 2028
-
6,7-unsaturated-7-carbamoyl substituted morphinan derivative
Patent RE46375
Issued: April 25, 2017
Inventor(s): Inagaki Masanao & Hara Shin-ichiro & Haga Nobuhiro & Tamura Yoshinori & Goto Yoshihisa & Hasegawa Tsuyoshi
Assignee(s): Shionogi & Co., Ltd.A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation.
Patent expiration dates:
- October 5, 2026✓✓✓
- October 5, 2026
More about Symproic (naldemedine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (34)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: peripheral opioid receptor antagonists
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
